Article
IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.
Molecular cancer therapeutics - 1 Feb 2015
Huang Fei, Chang Han, Greer Ann, Hillerman Stephen, Reeves Karen A, Hurlburt Warren, Cogswell John, Patel Dharmesh, Qi Zhenhao, Fairchild Craig, Ryseck Rolf-Peter, Wong Tai W, Finckenstein Friedrich G, Jackson Jeffrey, Carboni Joan M
Abstract excerpt
Insulin-like growth factor receptor 1 (IGF-1R)-targeting therapies are currently at an important crossroad given the low clinical response rates seen in unselected patients. Predictive biomarkers for patient selection are critical for improving clinical benefit. Coupling in vitro sensitivity testing of BMS-754807, a dual IGF-1R/IR inhibitor, with genomic interrogations in 60 human colorectal cancer cell lines, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.